Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease

Dementia and Geriatric Cognitive Disorders
Seong Hye ChoiMee Young Park

Abstract

The possible influence of apolipoprotein E (ApoE) genotype on the response to acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease (AD) remains a matter of controversy. In order to address this issue, we investigated the effects of ApoE genotype on the clinical response to donepezil in patients with mild to moderate AD. An open study was carried out in 51 patients with probable AD who were treated with 5-10 mg of donepezil per day for 48 weeks. Eighteen (35.3%) of the 51 patients had 1 or 2 ApoE epsilon4 alleles. ApoE epsilon4 carriers with AD showed a mean 1.1-point increase from the baseline score of 23.9 on the 70-point Alzheimer's Disease Assessment Scale-Cognitive Component at 48 weeks, while the ApoE epsilon4 noncarrier group showed a 3.1-point increase from the baseline score of 22.5 (p = 0.03). The ApoE epsilon4 carrier group exhibited a mean 0.13-point worsening from the baseline score of 0.97 on the Korean Instrumental Activities of Daily Living at 48 weeks, while the ApoE epsilon4 noncarrier group exhibited a 0.17-point worsening from the baseline score of 0.64 (p = 0.05). AD patients who carry the ApoE epsilon4 allele may respond more favorably to donepezil than epsilon4 noncarriers.

Citations

Sep 17, 2010·International Psychogeriatrics·Seong Hye ChoiSeol-Heui Han
Aug 6, 2015·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Kang Uk LeeJin Hyeong Jhoo
Jul 30, 2014·Frontiers in Aging Neuroscience·Sylvia VilleneuveDaniel Gaudet
Mar 12, 2011·Neuroscience and Biobehavioral Reviews·Laura A CraigRobert J McDonald
Dec 3, 2010·The EPMA Journal·Iris GrossmanAllen D Roses
Jun 24, 2017·American Journal of Alzheimer's Disease and Other Dementias·Ioana-Miruna Balmus, Alin Ciobica
Aug 5, 2018·Journal of Neurology, Neurosurgery, and Psychiatry·Hideyuki SawadaTakashi Kawamura
Feb 18, 2012·International Journal of Geriatric Psychiatry·Giuliano BinettiLuisa Benussi
Apr 24, 2013·Journal of Clinical Psychopharmacology·Yuan-Han YangSu-Hwei Chen
Sep 25, 2015·Journal of Alzheimer's Disease : JAD·Jeffrey F WaringLaura M Gault
Dec 14, 2011·Annals of Neurology·Andrew ChanManuel Comabella
Jun 11, 2020·Expert Opinion on Drug Metabolism & Toxicology·Ramón Cacabelos
Feb 25, 2020·Current Alzheimer Research·Marta KowalskaJolanta Dorszewska
Jul 17, 2009·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Motohiro NozawaHeii Arai
Jun 12, 2017·The Kaohsiung Journal of Medical Sciences·Tzu-Hua ChenYuan-Han Yang
Jan 28, 2020·Journal of Alzheimer's Disease : JAD·Jianping JiaLuoyi Xu
May 27, 2015·Revue neurologique·J-C CorvolL Lacomblez
Dec 27, 2011·Pharmacology & Therapeutics·Haythum O TayebFrank I Tarazi

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.